Aug 22, 2024 7:00am EDT Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity
Aug 09, 2024 5:59pm EDT Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Jul 24, 2024 6:00am EDT Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Jul 11, 2024 7:15am EDT Skye Bioscience to Host Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” on July 24th
Jun 10, 2024 7:00am EDT Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
